| Carolyn A Hellman, DO | |
|
1405 Mill St, New London, WI 54961-2155 | |
| (920) 531-2000 | |
| (920) 531-2098 |
| Full Name | Carolyn A Hellman |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 1405 Mill St, New London, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497789929 | NPI | - | NPPES |
| 930126462 | Other | WI | MEDICARE RAILROAD |
| 34305900 | Medicaid | WI | |
| 930126463 | Other | WI | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 44708-021 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Calumet Hospital | Chilton, WI | Hospital |
| St Mary's Hospital Medical Center | Green bay, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Calumet Hospital Inc | 7416948427 | 14 |
| Emergency Medicine Specialists Sc | 8729975461 | 195 |
| Green Bay Emergency Physicians, Llc | 6901879303 | 19 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Entity Name | St Josephs Hospital Of The Hospital Sisters Of The Third Order Of St F |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164429908 PECOS PAC ID: 3870488596 Enrollment ID: O20040220000036 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Entity Name | Emergency Medicine Specialists Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568413524 PECOS PAC ID: 8729975461 Enrollment ID: O20040228000032 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Entity Name | Door County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093743874 PECOS PAC ID: 5395735088 Enrollment ID: O20040514000588 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Entity Name | Ihc-st Nicholas Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245288836 PECOS PAC ID: 2264403021 Enrollment ID: O20040804001040 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Entity Name | Ascension Calumet Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376541748 PECOS PAC ID: 7416948427 Enrollment ID: O20040809000191 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Entity Name | Green Bay Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588612212 PECOS PAC ID: 6901879303 Enrollment ID: O20040813001226 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Entity Name | Ihc-sacred Heart Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992847826 PECOS PAC ID: 7113023391 Enrollment ID: O20070504000049 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carolyn A Hellman, DO 3 Neenah Ctr, Neenah, WI 54956-3070 Ph: (920) 830-5900 | Carolyn A Hellman, DO 1405 Mill St, New London, WI 54961-2155 Ph: (920) 531-2000 |
News Archive
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
New research has shown abnormalities in the tiny blood vessels of human hearts in regions well beyond the large arteries with atherosclerotic blockages that trigger the need for stents or bypass surgery.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.
› Verified 4 days ago
Ronald J Krajnik, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2021 | |
James John Macneal, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2030 Fax: 920-531-2016 | |
Shawn S Williamson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2021 | |
Joseph R James, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2000 | |
Amber Lievens Widenski, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2030 | |
Jocko R Zifferblatt, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2000 | |
Dr. John A Watring, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2000 |